Metropolis Healthcare Ltd (METROPOLIS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Metropolis Healthcare Ltd on NSE and BSE, with an AI summary of each filing.
Link of the audio recording of the earnings conference call held on November 04, 2026
Audio / Video · 04 Nov 2026, 9:28 pm
Metropolis Healthcare Releases Q2 FY27 Earnings Call Audio Recording Metropolis Healthcare announced that the audio recording of its earnings conference call held on 4th Nov'26 at 09:00 a.m. IST is now available on the company's website. The call discussed the financial results for the quarter and half-year ended 30th Sep'26 (Q2 FY27), in compliance with Regulation 30 of SEBI LODR Regulations, 2015.
Press Release
Press Release · 04 Nov 2026, 1:13 am
Metropolis Healthcare Reports Strong Q2 FY27 With PAT Surging 43% YoY Metropolis Healthcare reported robust Q2 FY27 results, with revenue rising 15.8% YoY to ₹496.8 crore and PAT surging 42.7% YoY to ₹75.5 crore. EBITDA grew 23.9% YoY to ₹134.9 crore, with EBITDA margins expanding 180 bps to 27.2%. Volume growth remained healthy, with patient volumes up 10% YoY to 4.1 million and test volumes rising 11% YoY to 8.7 million. TruHealth and Specialty revenues each grew 20% YoY, while B2C revenue increased 17% YoY. The Board declared an interim dividend of ₹1 per share.
Investor Presentation for the quarter and half year ended September 30, 2026
Investor Presentation · 04 Nov 2026, 1:09 am
Metropolis Healthcare Reports Strong Q2 & H1FY27 Financial and Operational Performance Metropolis Healthcare reported Q2FY27 revenue of INR 496.8 Cr (up 15.8% YoY), EBITDA of INR 134.9 Cr (up 23.9% YoY; 27.2% margin, +180 bps YoY), and PAT of INR 75.5 Cr (up 42.7% YoY; 15.2% margin, +290 bps YoY). H1FY27 revenue reached INR 947.0 Cr (+16.2% YoY) with PAT at INR 132.4 Cr (+34.9% YoY). Growth was volume-driven without price hikes, with patient volumes up 10% YoY to 4.07 Mn and test volumes up 11% YoY to 8.68 Mn in Q2FY27. Specialty and TruHealth segments grew 20% YoY each.
Board approves Interim Dividend
Dividend · 04 Nov 2026, 1:04 am
Metropolis Healthcare Reports Strong Q2 FY27 Results; Approves Interim Dividend Metropolis Healthcare reported consolidated revenue from operations of INR 4,968.21 mn for the quarter ended 30th Sep'26, up 15.76% YoY from INR 4,291.91 mn and 10.35% QoQ. Consolidated net profit attributable to owners grew 43.04% YoY to INR 753.38 mn compared to INR 526.68 mn in Q2 FY26. Diluted EPS rose to INR 3.60 from INR 2.53 YoY. The Board declared an interim dividend of INR 1.00 per equity share (face value INR 2.00) with a record date of 9th Nov'26.
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026
Financial Result · 04 Nov 2026, 12:54 am
Metropolis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 12:48 am
Metropolis Healthcare Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 4,968 (+15.8% YoY | +10.4% QoQ) ■ EBITDA: 1,340 (+23.8% YoY | +20.5% QoQ) ■ EBITDA Margin (%): 27.0 (+176 bps YoY | +228 bps QoQ) ■ PAT: 753 (+43.0% YoY | +32.9% QoQ) ■ EPS (INR): 3.60 (+42.3% YoY | +31.9% QoQ)
Outcome of Board Meeting
Outcome · 04 Nov 2026, 12:44 am
Allotment of 65,600 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020
Others (Uncategorized) · 03 Nov 2026, 5:04 pm
Metropolis Healthcare Approves Fresh Stock Grants and Allots 65,600 Equity Shares Metropolis Healthcare’s Nomination and Remuneration Committee approved the grant of 24,060 RSUs at an exercise price of INR 2 per unit and 3,58,920 ESOPs at INR 449.69 per option under its 2025 plans on 3rd Nov'26, both carrying a 1–4 year vesting period. Additionally, the committee allotted 65,600 equity shares (face value INR 2) aggregating to INR 1.31 lakh under the MHL-RSU Plan 2020. Post-allotment, issued share capital expanded to INR 41.51 cr (20,75,28,996 shares), with 50% of allotted shares subject to a one-year lock-in expiring 2nd Nov'27.
Grant of Stock Benefits
Others (Uncategorized) · 03 Nov 2026, 4:58 pm
Metropolis Healthcare Approves Stock Grants and Equity Allotment Metropolis Healthcare’s Nomination and Remuneration Committee approved the grant of 24,060 RSUs at INR 2 per unit and 3,58,920 ESOPs at INR 449.69 per option under the 2025 Plans on 3rd Nov'26, both carrying a 1-to-4-year vesting schedule. Additionally, the committee allotted 65,600 equity shares at an exercise price of INR 2 each (aggregating INR 1,31,200) under the MHL-RSU Plan 2020. Consequently, total issued share capital increased to INR 41,50,57,992 across 20,75,28,996 shares, with 50% of newly allotted shares subject to a one-year lock-in expiring 2nd Nov'27.
The Company will participate in the Q2FY27 earnings conference call (i.e. post earnings/quarterly call), organized by BNP Paribas Securities India on Wednesday, November 04, 2026 at 09:00 ....
Intimation · 04 Nov 2026, 9:00 am
Metropolis Healthcare Schedules Q2FY27 Earnings Conference Call Metropolis Healthcare Limited will host its Q2FY27 earnings conference call on 4th Nov'26 at 09:00 AM IST to discuss financial results for the quarter and half-year ended 30th Sep'26. Organized by BNP Paribas Securities India, the call will feature senior leadership, including Chairperson Ameera Shah, Managing Director Surendran Chemmenkotil, and CFO Sameer Patel. Universal dial-in numbers are +91 22 6280 1552 and +91 22 7115 8370, alongside international toll-free access for Hong Kong, Singapore, Australia, and the UK.
METROPOLIS HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
Intimation · 03 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and dividend
Intimation · 03 Nov 2026, 5:30 am
Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve a) Un-audited standalone ....
Intimation · 03 Nov 2026, 5:30 am
Metropolis Healthcare Board to Consider Q2FY27 Results and Interim Dividend Metropolis Healthcare has scheduled a Board of Directors meeting for 3rd Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the board will evaluate the declaration of an interim dividend on equity shares for FY26-27. In compliance with insider trading regulations, the company's trading window remains closed from 1st Oct'26 through 5th Nov'26 (both days inclusive).
Allotment of 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020
Others (Uncategorized) · 14 Oct 2026, 10:16 pm
Metropolis Healthcare Allots 9,516 Equity Shares Under RSU Plan 2020 Metropolis Healthcare's Nomination and Remuneration Committee approved the allotment of 9,516 equity shares on 14th Oct'26 under the Metropolis-Restrictive Stock Unit Plan, 2020. The shares were issued at an exercise price of INR 2 each, aggregating to INR 19,032. Following this allotment, the company's total issued shares increased to 20,74,63,396, corresponding to a total issued share capital of INR 41,49,26,792. Additionally, 50% of the allotted shares are subject to a one-year lock-in expiring on 13th Oct'27, ranking pari-passu with existing shares.
Business update for Q2FY27
Others (Uncategorized) · 05 Oct 2026, 11:42 pm
Metropolis Healthcare Reports Strong Q2FY27 Revenue and EBITDA Margin Growth Metropolis Healthcare reported approximately 15% YoY consolidated revenue growth for Q2FY27, ending 30th Sep'26. Topline growth was primarily driven by double-digit patient and test volume increases, supported by improved realizations and an enhanced product mix. TruHealth Wellness and Specialty emerged as the fastest-growing segments during the quarter. Additionally, EBITDA margins improved meaningfully on both a YoY and QoQ basis, bolstered by operating leverage and efficiency gains. Detailed financial results remain subject to auditor review.
Allotment of 66,312 equity shares under the Metropolis- Restrictive Stock Unit Plan, 2020
Others (Uncategorized) · 09 Sept 2026, 11:38 pm
Metropolis Healthcare Approves Equity Allotment Under MHL-RSU Plan 2020 Metropolis Healthcare's Nomination and Remuneration Committee approved the allotment of 66,312 equity shares on 9th Sep'26 following RSU exercises under the MHL-RSU Plan, 2020. Issued at an exercise price of INR 2 per share (aggregating to INR 1,32,624), the allotment expands total issued equity share capital to INR 41,49,07,760 across 20,74,53,880 shares. The newly issued shares rank pari-passu with existing stock, with 50% subject to a one-year lock-in expiring on 8th Sep'27.
Disclosure under Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 08 Sept 2026, 12:31 am
Metropolis Healthcare Subsidiary Restructures Shareholding via Strategic Equity Agreements Metropolis Healthcare’s subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), approved a Share Subscription and Shareholders' Agreement on 7th Sep'26 with Medsource Ozone Biomedicals and Dr. Puneet Kumar Nigam to scale its External Quality Assessment Services. Medsource and Dr. Puneet will invest ~INR 1.10 crore and ~INR 16 lakh, respectively. Following transaction closure and the 5-year phased conversion of 10,000 preference shares, MQSPL’s fully diluted equity structure will adjust from 100% wholly owned by Metropolis to 54.90% Metropolis, 30.60% Medsource, and 14.50% Dr. Puneet.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Franklin Templeton Mutual Fund
Acquisition/ Disposal of Shares · 07 Sept 2026, 9:03 pm
Franklin Templeton Increases Metropolis Healthcare Stake to 5.100% via Open Market Franklin Templeton Mutual Fund acquired 7,42,409 equity shares (0.358% stake) of Metropolis Healthcare Ltd via open-market purchases on 4th Sep'26 through Franklin India Opportunities Fund. This transaction raised Franklin Templeton's aggregate holding across its schemes from 9,835,345 shares (4.742%) to 10,577,754 shares (5.100%) of total voting capital, crossing the 5% regulatory disclosure threshold. Total post-acquisition equity capital remains at 207,387,568 shares.
Transcript of Investors & Analyst Meet held on Thursday, August 27, 2026
Transcript · 03 Sept 2026, 12:28 am
Audio recording of the Investors & Analyst Meet
Audio / Video · 28 Aug 2026, 4:42 am
Metropolis Healthcare Makes Investor & Analyst Meet Recording Available Metropolis Healthcare has made the audio recording of its Investors & Analyst Meet available on its website. The meeting was held on 27 Aug'26 at 4:00 p.m. IST. This filing complies with SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. Investors can access the recording via the link provided in the official stock exchange notification.
Disclosure under Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 28 Aug 2026, 12:45 am
Metropolis Healthcare Transfers EQAS Division to Subsidiary Metropolis Healthcare has transferred its External Quality Assessment Services (EQAS) division to its subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), effective Aug 27, '26. The transfer was conducted as a going concern on a slump sale basis for a consideration of INR 1.25 crore. This consideration was discharged via the issuance of equity shares of MQSPL to the parent company. Operations of the EQAS division are now managed by MQSPL.
Investor Presentation
Investor Presentation · 27 Aug 2026, 9:09 pm
Metropolis Guides for 14-15% Revenue Growth and Margin Expansion Toward 27-28% Metropolis Healthcare provided a strong FY27 outlook, guiding for 14-15% full-year revenue growth without price increases, starting ahead of trajectory with 17% YoY growth in Q1 FY27. EBITDA margins are guided to improve by 100-150 bps and are targeted to reach 27-28% over three years, up from 24.4%. Growth drivers include volume expansion, network utilization, and increasing the specialty segment's revenue share from 40% to ~45%. The strategy focuses on scaling its B2C/B2B channels, expanding the TruHealth wellness segment, and selective inorganic growth.
Disclosure under Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 21 Aug 2026, 4:07 am
Metropolis to Issue Preference Shares in Subsidiary, Reducing Stake Metropolis Healthcare's subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), will issue Optionally Convertible Redeemable Preference Shares (OCRPS) worth INR 100,000. These will be allotted to Dr. Puneet Kumar Nigam, the company's former Chief Quality Officer. Upon conversion, MQSPL will cease to be a wholly-owned subsidiary but will remain a subsidiary. MQSPL, incorporated on 15 Sep'25, is yet to commence operations and has zero contribution to Metropolis's financials. The conversion is expected to occur in tranches over six years.
Schedule of Analyst / Institutional Investor Meeting
Intimation · 20 Aug 2026, 11:20 pm
Metropolis Healthcare Schedules Analyst and Investor Meet Metropolis Healthcare has scheduled an analyst and institutional investor group meeting on 27 Aug'26, starting at 4:00 PM IST. The company confirmed that discussions will be based on publicly available information and no unpublished price-sensitive information (UPSI) is intended to be disclosed during the interaction. The meeting's schedule is subject to potential changes.
Scrutinizer''s Report for the 26th Annual General Meeting
Annual General Meeting · 20 Aug 2026, 2:13 am